Trial Profile
A Two-Period, Open-label Trial Evaluating the Efficacy and Safety of Dasiglucagon for the Treatment of Children with Congenital Hyperinsulinism
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Dec 2023
Price :
$35
*
At a glance
- Drugs Dasiglucagon (Primary)
- Indications Congenital hyperinsulinism
- Focus Registrational; Therapeutic Use
- Sponsors Zealand Pharma
- 01 Nov 2023 Results evaluating the efficacy and safety of dasiglucagon in children with CHI and persistent hypoglycaemia as add-on to standard of care (SoC), published in the Journal of Clinical Endocrinology and Metabolism.
- 30 Aug 2023 According to a Zealand Pharma media release, to ensure the most efficient regulatory process, the review by the US FDA will be conducted in two parts under NDA. Part 1 relates to dosing for up to 3 weeks, whereas Part 2 relates to use beyond 3 weeks; The PDUFA date for Part 2 will be set following submission of additional analyses from existing datasets requested by the US FDA, which is expected before the end of the year.
- 30 Aug 2023 According to a Zealand Pharma media release, US FDA has granted priority review designation to dasiglucagon for the prevention and treatment of hypoglycemia in pediatric patients 7 days of age and older with congenital hyperinsulinism (CHI) for up to 3 weeks of dosing with a Prescription Drug User Fee Act (PDUFA) date on December 30, 2023